TY - JOUR
T1 - Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons
AU - Brod, Staley A.
AU - Burns, Dennis K.
PY - 1994/6
Y1 - 1994/6
N2 - We induced a chronic relapsing form of experimental autoimmune encephalomyelitisin 7- to 10-week-old female SJL/J mice using a subcutaneous injection of an emulsion containing syngeneic mouse spinal cord homogenate in phosphate-buffered saline and Mycobacterium tuberculosis (MT) in incomplete Freund's adjuvant. Following the animals' recovery from the first attack periods, we fed them varying doses of type I interferon(IFN) or mock IFN three times per week for 6 weeks. This treatment decreased proliferation to guinea pig myelin basic protein and MT compared with control in draining lymph node and diminished inflammation in the CNS. Oral IFN altered the cytokine profile of concanavalin A-activated spleen cells by decreasing IFN-γ secretion. These results suggestthat type I IFNs are active by the oral route, have significant clinical and immunomodulatory effects, and can decrease an established and ongoing immune response to sensitized antigens. The oral administration of biologic-response modifiers, such as type I IFNs, provides a potentially nontoxic, convenient, continuous means of delivering immunoactive substances via the gut regional immune system that can alter cytokine production and suppress clinical relapses.
AB - We induced a chronic relapsing form of experimental autoimmune encephalomyelitisin 7- to 10-week-old female SJL/J mice using a subcutaneous injection of an emulsion containing syngeneic mouse spinal cord homogenate in phosphate-buffered saline and Mycobacterium tuberculosis (MT) in incomplete Freund's adjuvant. Following the animals' recovery from the first attack periods, we fed them varying doses of type I interferon(IFN) or mock IFN three times per week for 6 weeks. This treatment decreased proliferation to guinea pig myelin basic protein and MT compared with control in draining lymph node and diminished inflammation in the CNS. Oral IFN altered the cytokine profile of concanavalin A-activated spleen cells by decreasing IFN-γ secretion. These results suggestthat type I IFNs are active by the oral route, have significant clinical and immunomodulatory effects, and can decrease an established and ongoing immune response to sensitized antigens. The oral administration of biologic-response modifiers, such as type I IFNs, provides a potentially nontoxic, convenient, continuous means of delivering immunoactive substances via the gut regional immune system that can alter cytokine production and suppress clinical relapses.
UR - http://www.scopus.com/inward/record.url?scp=0028236020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028236020&partnerID=8YFLogxK
U2 - 10.1212/wnl.44.6.1144
DO - 10.1212/wnl.44.6.1144
M3 - Article
C2 - 8208413
AN - SCOPUS:0028236020
SN - 0028-3878
VL - 44
SP - 1144
EP - 1148
JO - Neurology
JF - Neurology
IS - 6
ER -